RxDoctor Payments Data

Glenne Gunther, MD

Internal Medicine · Libby, MTNPI 1629044276

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $105, 2.0 times the $52 reported in 2019.

$480in general payments, 2019–2025

Across 26 payments — averaging $18.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$103
  • Amgen$75
  • Ultragenyx Pharmaceutical Inc.$57
  • CSL Behring$45
  • Exact Sciences$43
  • Boston Scientific$39
  • plus $118 from 7 others

What the payments were for

  • Food & beverage$480100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$480 in reported general payments places this provider in the 85th percentile of 244 internal medicine providers in Montana.

See all internal medicine providers in Montana

Medicare billing

Part B allowed, 2024
$5,997
Medicare patients
193
Services billed
371

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HaegardaC1 Esterase Inhibitor13$435,116
JardianceEmpagliflozin103$80,790
EliquisApixaban125$69,399
TrulicityDulaglutide51$52,931
OzempicSemaglutide38$46,955
RybelsusSemaglutide14$26,031
XareltoRivaroxaban41$25,105
FarxigaDapagliflozin Propanediol17$22,161
Lurasidone Hcl17$13,086
EntrestoSacubitril/Valsartan26$12,683
Spiriva RespimatTiotropium Bromide11$12,643
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$11,619
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog29$11,139
Breo ElliptaFluticasone/Vilanterol22$8,615
Incruse ElliptaUmeclidinium Bromide23$8,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHaegarda$45$435,11613 claims
Novo NordiskOzempic, Rybelsus$103$72,98652 claims
PfizerEliquis$12$69,399125 claims
Lilly USA, LLCTrulicity$17$52,93151 claims
AstraZenecaFarxiga, Symbicort$13$26,84532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 244 internal medicine providers in Montana.

Other internal medicine in Libby

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →